Search PubMedSearch

PubMed · 1180308

Hemolytic glaucoma.

Abstract

The clinical manifestations of hemolytic glaucoma in five patients showed that the glaucoma began after a large intraocular hemorrhage. Gonioscopy revealed open angles in the anterior chamber and reddish-brown pigment covering the trabecular meshwork. Numerous red-tinted blood cells were floating in the aqueous humor; some of these were macrophages found by cytologic examination to contain golden-brown pigment granules. The presumed cause of hemolytic glaucoma is obstruction of the trabecular meshwork by fragments of hemolyzed red blood cells and hemoglobin-laden macrophages. Two patients, whose intraocular pressures were not decreased with medication, improved remarkably after irrigation of hemolytic debris from the anterior chamber.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

C D Phelps, R C Watzke. 1975. Hemolytic glaucoma.. https://doi.org/10.1016/0002-9394(75)90401-8

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

[Cerebrovascular reactivity in insulin dependent diabetes mellitus studied by an acetazolamide test].

The aim of this study was to investigate, whether the cerebrovascular reactivity (CR) was altered in diabetes mellitus and to evaluate the influence of diabetes's duration on cerebrovascular reactivity. Transcranial Doppler-Acetazolamide tests were performed on 20 insulin-dependent diabetics and in 19 controls. Patients were divided into two groups, each group consisted of 10 patients: diabetics with > 10 years disease duration and with < 10 years diseases duration. Middle cerebral artery mean velocities were measured at rest and after i.v. administration of Ig Acetazolamide (AZ). There were no differences in the absolute velocities between controls and diabetics. The percentual increase of the mean velocity after AZ was slower and less intensive in longterm diabetics (means +/- SE: 5 min: 19.4 +/- 2.8%, 10 min: 28 +/- 3.6%, 15 min: 25.7 +/- 3.8%, 20 min: 23.9 +/- 4.3%), than that in controls (5 min: 32.3 +/- 4.3% -p < 0.05-, 10 min: 45.1 +/- 4.9% -p < 0.05-, 15 min: 47.5 +/- 4.3% -p < 0.01-, 20 min: 46.5 +/- 4.7% -p < 0.01) as well as in diabetics with < 10 years disease duration (5 min.: 39.5 +/- 7% -p < 0.05-, 10 min.: 49.2 +/- 6.5% -p < 0.05-, 15 min.: 53.9 +/- 8.6% -p < 0.01-, 20 min: 32.9 +/- 5.9% -n.s.). The cerebrovascular reactivity is impaired in diabetics after long duration of the disease. The altered cerebrovascular reactivity might be caused by angiopathy of the cerebral arterioles.

Acetazolamide

Stability of acetazolamide, allopurinol, azathioprine, clonazepam, and flucytosine in extemporaneously compounded oral liquids.

The stability of drugs commonly prescribed for use in oral liquid dosage forms but not commercially available as such was studied. Acetazolamide 25 mg/mL, allopurinol 20 mg/mL, azathioprine 50 mg/mL, clonazepam 0.1 mg/mL, and flucytosine 10 mg/mL were prepared in 1:1 mixture of Ora-Sweet and Ora-Plus (Paddock Laboratories), a 1:1 mixture of Ora-Sweet SF and Ora-Plus (Paddock Laboratories), and cherry syrup and placed in polyethylene terephthalate bottles. The sources of the drugs were capsules and tablets. Six bottles were prepared per liquid; three were stored at 5 degrees C and three at 25 degrees C, all in the dark. A sample was removed from each bottle initially and at intervals up to 60 days and analyzed for drug concentration by stability-indicating high-performance liquid chromatography. At least 94% of the initial drug concentration was retained in all the oral liquids for up to 60 days. There were no substantial changes in the appearance or odor of the liquids, or in the pH. Acetazolamide 25 mg/mL, allopurinol 20 mg/mL, azathioprine 50 mg/mL, clonazepam 0.1 mg/mL, and flucytosine 10 mg/mL were stable for up to 60 days at 5 and 25 degrees C in three extemporaneously compounded oral liquids.

Acetazolamide

The effect of low-dose acetazolamide on the ventilatory CO2 response curve in the anaesthetized cat.

1. The effect of 4 mg kg-1 acetazolamide (I.V.) on the slope (S) and intercept on the Pa,CO2 axis (B) of the ventilatory CO2 response curve of anaesthetized cats with intact or denervated carotid bodies was studied using the technique of dynamic end-tidal forcing. 2. This dose did not induce an arterial-to-end-tidal PCO2 (P(a-ET),CO2) gradient, indicating that erythrocytic carbonic anhydrase was not completely inhibited. Within the first 2 h after administration, this small dose caused only a slight decrease in mean standard bicarbonate of 1.8 and 1.7 mmol l-1 in intact (n = 7) and denervated animals (n = 7), respectively. Doses of acetazolamide larger than 4 mg kg-1 (up to 32 mg kg-1) caused a significant increase in the P(a-ET),CO2 gradient. 3. In carotid body-denervated cats, 4 mg kg-1 acetazolamide caused a decrease in the CO2 sensitivity of the central chemoreflex loop (Sc) from 1.52 +/- 0.42 to 0.96 +/- 0.32 l min-1 kPa-1 (mean +/- S.D.) while the intercept on the Pa,CO2 axis (B) decreased from 4.5 +/- 0.5 to 4.2 +/- 0.7 kPa. 4. In carotid body-intact animals, 4 mg kg-1 acetazolamide caused a decrease in the CO2 sensitivity of the peripheral chemoreflex loop (Sp) from 0.28 +/- 0.18 to 0.19 +/- 0.12 l min-1 kPa-1. Se and B decreased from 1.52 +/- 0.55 to 0.84 +/- 0.21 l min-1 kPa-1, and from 4.0 +/- 0.5 to 3.0 +/- 0.6 kPa, respectively, not significantly different from the changes encountered in the denervated animals. 5. It is argued that the effect of acetazolamide on the CO2 sensitivity of the peripheral chemoreflex loop in intact cats may be caused by a direct effect on the carotid bodies. Both in intact and in denervated animals the effects of the drug on Sc and B may not be due to a direct action on the central nervous system, but rather to an effect on cerebral vessels resulting in an altered relationship between brain blood flow and brain tissue PCO2.

Acetazolamide